π’ ππππ ππ: Novo Nordisk to Seek China Approval for Oral Wegovy Within Months - $Novo Nordisk AS(NVO.US) $Eli Lilly(LLY.US) $Hims & Hers Health(HIMS.US)
π πππ² ππ’π π‘π₯π’π π‘ππ¬:β€ Novo Nordisk plans to file for China approval of oral Wegovy within months.β€ CEO Mike Doustdar announced the timeline during his first China visit as CEO.β€ Oral weight-loss drugs target patients reluctant to use injections.β€ Novo and Eli Lilly are competing for China's obesity treatment market.β€ Lilly submitted a China marketing application for orforglipron in late 2025.β€ China's semaglutide patent expired in March; data protection lasts until early 2027.β€ Novo expects generic competition beginning in Q2 2027.β€ Novo says large-scale manufacturing could be a key barrier for competitors.β€ Oral Wegovy has secured approvals in the U.S. and U.K., with a U.S. launch underway.β€ China GLP-1 sales reached about Yuan 1.4 billion ($207 million) in Q1.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments